CRESSET BIOMOLECULAR DISCOVERY LIMITED
Get an alert when CRESSET BIOMOLECULAR DISCOVERY LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-12-31 (in 7mo)
Last filed for 2025-03-31
Confirmation statement due
2026-10-14 (in 5mo)
Last made up 2025-09-30
Watchouts
None on the register
Cash
£2M
+44.9% vs 2021
Net assets
£2M
+51.2% vs 2021
Employees
46
+48.4% vs 2021
Profit before tax
—
Period ending 2022-03-31
Net assets
2-year trend · vs Technology median
Accounts
2-year trend · latest reflected 2022-03-31
Latest accounts filed cover 2025-03-31; financial figures currently reflect up to 2022-03-31.
| Metric | Trend | 2021-03-31 | 2022-03-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | — | — | |
| Profit before tax | — | — | |
| Net profit | — | — | |
| Cash | £1,393,693 | £2,019,479 | |
| Total assets less current liabilities | £1,442,429 | £2,125,598 | |
| Net assets | £1,393,027 | £2,106,901 | |
| Equity | £1,393,027 | £2,106,901 | |
| Average employees | 31 | 46 | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements have been prepared on a going concern basis, which assumes that Cresset will continue in operational existence for at least twelve months from the date these financial statements are approved. Based on forecasts and stress test scenarios, considering existing funds and the capital raise after the year-end, the Directors determine that Cresset will have sufficient cash for the next twelve months and as such can be considered a going concern.”
Group structure
- CRESSET BIOMOLECULAR DISCOVERY LIMITED · parent
- Cresset Biomolecular Discovery Inc 100%
- Cresset Biomolecular Discovery (India) Private Limited 100%
Significant events
- “Cresset acquired Molab.ai GmbH on 18 June 2025, a pioneer in artificial intelligence technologies tailored for molecular research.”
- “Further capital by way of an ordinary share issue of 4,438 shares for consideration of £1,126.68 per share was raised on 14 August 2025 to support the growth plans of the Group.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
8 active · 17 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| SCUTT, Rebecca | Secretary | 2017-05-04 | — | — |
| CHEESERIGHT, Timothy John, Dr | Director | 2013-04-17 | Aug 1966 | British |
| CONROY, Angus Mark | Director | 2022-09-15 | Jun 1988 | British |
| CURTIS JR, Dale | Director | 2024-05-01 | Oct 1976 | American |
| MACKEY, Mark Denis, Dr | Director | 2011-03-16 | Aug 1971 | Australian |
| NEWBLE, David Allan | Director | 2021-10-14 | Jan 1971 | British |
| SCOFFIN, Robert Arthur, Dr | Director | 2010-04-19 | Jan 1966 | British |
| SCUTT, Rebecca Jane | Director | 2020-02-13 | Sep 1974 | British |
Show 17 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HALLS, Raymond David | Secretary | 2001-01-31 | 2005-08-31 |
| ROSE, Valerie Sarah, Dr | Secretary | 2005-09-01 | 2008-08-27 |
| VINTER, Jeremy Gilbert, Dr | Secretary | 2008-08-27 | 2017-05-04 |
| ASHWORTH, Philip Anthony, Dr | Director | 2001-01-31 | 2002-09-10 |
| BARDSLEY, David William, Dr | Director | 2013-04-17 | 2024-05-14 |
| COWEN, Andrew Edward | Director | 2008-10-01 | 2013-04-10 |
| GARDNER, Stephen Philip, Dr | Director | 2011-01-01 | 2013-03-26 |
| HALLS, Raymond David | Director | 2001-01-31 | 2006-07-25 |
| HAYNES, Richard John | Director | 2009-07-14 | 2013-04-08 |
| HILLIER, Paul Ashley | Director | 2001-01-31 | 2006-07-25 |
| LAMONT, Alan Gordon | Director | 2001-11-14 | 2002-07-18 |
| LEIGH, Beatrice Katherine | Director | 2004-05-01 | 2011-09-08 |
| LEIGHTON, John Perrot | Director | 2023-04-11 | 2026-03-23 |
| MCPARTLAND, Peter | Director | 2002-09-01 | 2006-12-20 |
| ROSE, Valerie Sarah, Dr | Director | 2007-05-01 | 2008-08-27 |
| ROSE, Valerie Sarah, Dr | Director | 2004-07-20 | 2006-07-25 |
| VINTER, Jeremy Gilbert, Dr | Director | 2001-01-31 | 2019-12-16 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Sep Vi L.P. | Corporate entity | Shares 25–50%, Voting 25–50% | 2022-09-15 | Active |
| Dr Jeremy Gilbert Vinter | Individual | Shares 25–50% | 2016-04-06 | Ceased 2020-12-08 |
Filing timeline
Last 20 of 202 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-03-23 | TM01 | officers | Termination director company with name termination date | |
| 2025-12-19 | AA | accounts | Accounts with accounts type group | |
| 2025-12-18 | SH01 | capital | Capital allotment shares | |
| 2025-10-21 | SH01 | capital | Capital allotment shares | |
| 2025-09-30 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-08-21 | SH01 | capital | Capital allotment shares | |
| 2025-08-21 | MA | incorporation | Memorandum articles | |
| 2025-08-21 | RESOLUTIONS | resolution | Resolution | |
| 2025-08-19 | SH01 | capital | Capital allotment shares | |
| 2025-05-12 | SH01 | capital | Capital allotment shares | |
| 2025-04-02 | AA | accounts | Accounts with accounts type group | |
| 2025-03-31 | SH01 | capital | Capital allotment shares | |
| 2025-01-09 | SH01 | capital | Capital allotment shares | |
| 2025-01-08 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2025-01-07 | SH01 | capital | Capital allotment shares | |
| 2024-12-28 | RESOLUTIONS | resolution | Resolution | |
| 2024-12-17 | SH01 | capital | Capital allotment shares | |
| 2024-11-26 | CH01 | officers | Change person director company with change date | |
| 2024-11-26 | CH01 | officers | Change person director company with change date | |
| 2024-11-25 | CH01 | officers | Change person director company with change date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 10
- Capital events
- 10
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2021 → FY2022 · period ending 2022-03-31 vs 2021-03-31
-
Turnover
—
Not reported
-
Cash
+44.9%
£1,393,693 £2,019,479
-
Net assets
+51.2%
£1,393,027 £2,106,901
-
Employees
+48.4%
31 46
Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers